News & Events
Public Meeting on Economically Motivated Adulteration
May 1, 2009
9:00 a.m. - 5:00 p.m.
Harvey W. Wiley Federal Building
U.S. Food and Drug Administration
5100 Paint Branch Parkway
College Park, MD 20740-3835
Docket No: FDA-2009-N-0166
The U.S. Food and Drug Administration is announcing a Public Meeting pertaining to economically motivated adulteration (EMA). The purpose of the meeting is to stimulate and focus a discussion about ways in which the food, (including dietary supplements and animal food), drug, medical device and cosmetic industries, regulatory agencies, and other parties can better predict and prevent economically motivated adulteration. FDA invites interested individuals, organizations, and other stakeholders, including industry representatives, to present information pertaining to predicting and preventing EMA of food, (including dietary supplements and animal food), drugs, medical devices and cosmetics. The agency also requests interested parties to submit comments on this issue to the public docket.
For general questions about the meeting, to request on-site parking or for special accommodations due to a disability, contact: Juanita Yates, Center for Food Safety and Applied Nutrition, 301-436-1731, e-mail: juanita.yates@fda.hhs.gov.
Presentations
The following slides will be available until June 3, 2009, at which time the FDA will provide a fully accessible version of the content or remove it from the site.
Addressing Challenges of Economically-Motivated Adulteration
Presenter: Randall Lutter, Ph.D., Deputy Commissioner for Policy, Food and Drug Administration
Text version
Defining Food Fraud & The Chemistry of the Crime
Presenter: John Spink, Ph.D., Associate Director Anti-Counterfeiting and Product Protection Program (A-CAPPP), School of Criminal Justice
Economically Motivated Adulteration
Roger L. Williams, M.D., Chief Executive Officer Chair, Council of Experts, U.S. Pharmacopeia
Efforts to Ensure Excipient Safety
Irwin Silverstein, IPEC Americas, Inc.
Economically Motivated Adulteration
Martin VanTrieste, Vice President Quality; Commercial Operations, Amgen
Summary of Comments: Economically Motivated Adulteration
Lisa Weddig, National Fisheries Institute
Director, Regulatory and Technical Affairs
Secretary, Better Seafood Board
Suspected Economically Motivated Adulteration of FDA-Regulated Products
John E. Bailey, Executive Vice President - Science Personal Care Products Council
Economically Motivated Adulteration
Daniel Fabricant, Ph.D. Vice President, Scientific & Regulatory Affairs, Natural Products Association
Simple Authentication Methods for Herbal Ingredient Integrity in the face of EMA
Steven Dentali, Ph.D., Chief Science Officer, American Herbal Products Association
Avoiding economic adulteration of dietary supplements: The need for ingredient supplier qualification guidelines
Andrew Shao, Ph.D., Vice President, Scientific & Regulatory Affairs, Council for Responsible Nutrition
Economically Motivated Adulteration in the Dietary Supplement Market Place
William Obermeyer Ph.D., VP Research, ConsumerLab.com
Protecting Consumers from Adulterated Drugs
Allan Coukell, Director, Pew Prescription Project, The Pew Charitable Trusts
Comments on Economically Motivated Adulteration
Xuman Amanda Tian, Research Associate, Food Safety Program, Center for Science in the Public Interest
Economically Motivated Adulteration
Craig W. Henry Ph.D., Senior Vice President and Chief Operating Officer, Scientific and Regulatory Affairs
Grocery Manufacturers Association
Accessibility Information
Persons with disabilities having problems accessing the above ppt file may call Tina Gilliam, 301-827-7133 for assistance.
